图文详情
The peptide VVVGASGVGK, derived from the KRAS G12S mutation and presented by the HLA-A*11:01/β2-microglobulin (β2m) complex, is a pivotal antigenic target in antitumor immunity. This complex plays a crucial role by activating specific cytotoxic T lymphocytes (CTLs), enabling the immune system to recognize and eliminate tumor cells harboring the KRAS G12S mutation.